Literature DB >> 12763222

Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines.

H H J Backus1, D Wouters, C G Ferreira, V M M van Houten, R H Brakenhoff, H M Pinedo, G J Peters.   

Abstract

Thymidylate synthase (TS) is an important target for chemotherapy and increased levels are associated with resistance to colorectal cancer chemotherapy. TS can be inhibited by 5-fluorouracil (5-FU) and antifolates, ultimately resulting in apoptosis. We aimed to clarify whether activation of caspases and Fas signalling are crucial for the onset of apoptosis after specific inhibition of TS and whether p53 plays a role in activation of these downstream processes. For this purpose, wild-type (wt) and mutant (mt) p53 colon cancer cell lines, Lovo and WiDr, respectively, transfected with mt- and wt-p53, were treated with the specific TS inhibitor, AG337. Treatment with 10xIC(50) values of AG337 for 48 h resulted in S phase arrest in all Lovo and WiDr cells (up to 50% of cells being in S phase), irrespective of their p53 status. After 72 h, the induction of apoptosis was most pronounced in the AG337-sensitive cells. Approximately 30% apoptosis was detected in all of the WiDr cells, 20% in Lovo li (non-functional p53), 12-14% in Lovo 92 and B2 (wt p53) and only 7% in Lovo 175x2 cells (mt p53 transfected). The induction of apoptosis in Lovo cells, as determined using the classical sub-G1 peak after propidium iodide (PI) staining, was associated with an increase in the expression of Fas receptor. In addition, synergistic increases in apoptosis from approximately 10 to 35% after 48 h could be detected after simultaneous treatment of AG337 and the Fas activator antibody, CH11. Only additive effects were measurable in WiDr cells, without an increase in Fas receptor expression. Surprisingly, the Fas inhibitor, ZB4, could not decrease the amount of cell death in both cell lines after AG337 treatment. In contrast, simultaneous exposure of Lovo and WiDr cells to AG337 and inhibitors of caspases 8, 9 and 3 caused a decrease in the number of apoptotic cells compared with AG337 exposure alone. Inhibition of apoptosis by approximately 10-80% in Lovo and approximately 70-80% in WiDr cells could be detected. In conclusion, these results indicate that apoptosis induced after specific inhibition of TS is mediated via the caspases, but without clear involvement of Fas signalling. The status of p53 did not affect the onset of apoptosis by these caspases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763222     DOI: 10.1016/s0959-8049(03)00204-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

1.  Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.

Authors:  Stefania Giudice; Luisa Benassi; Giorgia Bertazzoni; Eugenia Veratti; Daria Morini; Paola Azzoni; Maria P Costi; Alberto Venturelli; Silvia Pirondi; Stefania Seidenari; Cristina Magnoni
Journal:  Invest New Drugs       Date:  2011-09-01       Impact factor: 3.850

2.  Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells.

Authors:  Dimitrios J Stravopodis; Panagiotis K Karkoulis; Eumorphia G Konstantakou; Sophia Melachroinou; Angeliki Thanasopoulou; Gerasimos Aravantinos; Lukas H Margaritis; Ema Anastasiadou; Gerassimos E Voutsinas
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-28       Impact factor: 4.553

3.  Synthesis, characterization and molecular docking studies of thiouracil derivatives as potent thymidylate synthase inhibitors and potential anticancer agents.

Authors:  Abeer M El-Naggar; Mohsen M Abou-El-Regal; Souad A El-Metwally; Farag F Sherbiny; Ibrahim H Eissa
Journal:  Mol Divers       Date:  2017-08-16       Impact factor: 2.943

4.  Discovery of safe and orally effective 4-aminoquinaldine analogues as apoptotic inducers with activity against experimental visceral leishmaniasis.

Authors:  Partha Palit; Abhijit Hazra; Arindam Maity; R S K Vijayan; Prabu Manoharan; Sukdeb Banerjee; Nirup B Mondal; Nanda Ghoshal; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

5.  Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.

Authors:  Tiffany T Huang; Shraddha Parab; Ryan Burnett; Oscar Diago; Derek Ostertag; Florence M Hofman; Fernando Lopez Espinoza; Bryan Martin; Carlos E Ibañez; Noriyuki Kasahara; Harry E Gruber; Daniel Pertschuk; Douglas J Jolly; Joan M Robbins
Journal:  Hum Gene Ther       Date:  2015-01-19       Impact factor: 5.695

6.  Cancer and Apoptosis.

Authors:  Gul-E-Saba Chaudhry; Abdah Md Akim; Yeong Yik Sung; Tengku Sifzizul Tengku Muhammad
Journal:  Methods Mol Biol       Date:  2022

7.  Hsp70 response to 5-fluorouracil treatment in human colon cancer cell lines.

Authors:  Ivana Grivicich; Andréa Regner; Caroline Zanoni; Larissa Procópio Correa; Geraldo Pereira Jotz; João Antônio Pêgas Henriques; Gilberto Schwartsmann; Adriana Brondani da Rocha
Journal:  Int J Colorectal Dis       Date:  2007-03-28       Impact factor: 2.571

8.  The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells.

Authors:  María Angel García; Esther Carrasco; Margarita Aguilera; Pablo Alvarez; Carmen Rivas; Joaquin María Campos; Jose Carlos Prados; Miguel Angel Calleja; Mariano Esteban; Juan Antonio Marchal; Antonia Aránega
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

9.  Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.

Authors:  Wainer Zoli; Paola Ulivi; Anna Tesei; Francesco Fabbri; Marco Rosetti; Roberta Maltoni; Donata Casadei Giunchi; Luca Ricotti; Giovanni Brigliadori; Ivan Vannini; Dino Amadori
Journal:  Breast Cancer Res       Date:  2005-06-22       Impact factor: 6.466

10.  Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.

Authors:  E Giovannetti; H H J Backus; D Wouters; C G Ferreira; V M M van Houten; R H Brakenhoff; M-F Poupon; A Azzarello; H M Pinedo; G J Peters
Journal:  Br J Cancer       Date:  2007-03-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.